EU firms targeted in calls for new biomarkers and drug development tools
This article was originally published in RAJ Devices
Personalised medicine, biomarkers and systems biology are among the collaborative projects aimed specifically at small and medium-sized companies in the latest call for proposals under the EU's funding programme, FP71-3.
You may also be interested in...
As part of its efforts to preserve patient access to medicines amid the COVID-19 pandemic, Russia is planning to cap drug prices if increases of more than 30% are detected. It will also allow online sales of non-prescription drugs and may also tighten the rules on fake and substandard products.
France is exploring the use of hydroxychloroquine and lopinavir/ritonavir in COVID-19, but only in hospitalized patients and in clinical trials, and has banned all exports of the products to avoid possible shortages.
Efforts are under way in the UK on many fronts to develop new treatments and vaccines for coronavirus infection, including researching new uses of existing products and clinical trials of new vaccines.